Thor Medical strengthens executive team for alpha therapies leadership

Thor Medical ASA announced on November 18, 2025, the appointment of Therese Kvehaugen and Mathias Nilsen Reierth to its executive management team. These additions are expected to advance the company's ambition to become a global leader in the sustainable supply of alpha isotopes for targeted cancer therapies.

Therese Kvehaugen will assume the role of executive vice president, human resources, effective January 12, 2026, while Mathias Nilsen Reierth will become head of communications and corporate affairs no later than February 1, 2026. Both will report directly to chief executive Jasper Kurth.

Jasper Kurth emphasized that these appointments are crucial for Thor Medical's high ambitions and its goal of building an organization capable of making a meaningful impact on cancer patients and partners. Kvehaugen brings extensive international HR experience from the biotechnology industry, including leadership roles at Timbr, Nykode Therapeutics, Alnylam Pharmaceuticals, Rambøll, Biogen, and Franke. Reierth's background includes strategic communications in green industry and energy at Vow Green Metals, Aker Horizons, and Hafslund, alongside experience in journalism and management consulting.

Thor Medical specializes in supplying radionuclides, primarily alpha particle emitters derived from naturally occurring thorium, utilizing a proprietary production process that requires no irradiation or nuclear reactors. This method ensures a reliable, environmentally friendly, and cost-efficient supply of alpha-emitters for the radiopharmaceutical industry.